Small Cap Pharma Stock Trading Ex-Dividend Next Week For Rs 47.50/Share Dividend

Small cap stock opeating in pharmaceuticals sector, Novartis India Ltd is all set to trade ex-dividend on July 20, 2023 for 750% special dividend and 200% final dividend. The company declared total dividend of Rs 47.50 per equity share of the face value of Rs 5 each on May 10, 2023. Current market price of Novartis India share is Rs 862.50 per share on BSE. Novartis India stock offered 44% return in last 3-months. Check details below:

Novartis India Set To Go Ex-Dividend On July 20: According to the regulatory filing of Novartis India, "The Board has recommended the following dividend for the financial year ended March 31, 2023, subject to the approval of the shareholders of the Company at the ensuing Annual General Meeting (AGM):

a) Final dividend of 10.00 (Rupees Ten Only) per equity share of the face value of 5 each

b) One-time Special dividend of 37.50 (Rupees Thirty-Seven and Paise Fifty Only) per equity share of the face value of 5 each, on occasion of Company’s 75th Anniversary

The total dividend amounts to 47.50 (Rupees Forty-Seven and Paise Fifty Only) per equity share of the face value of 5 each. Accordingly, the dividend, if approved by the shareholders, will be paid on or after August 02,2023.

Novartis India Stock Performance & Return: Current market price of Novartis India share is Rs 861.35 per share with intraday gain of 0.25% on BSE. Its 52-week high price is Rs 876.45 per share and 52-week low price is Rs 554.00 per share, respectively. The company has a market capitalisation of Rs 2126.74 crore.
Novartis India share soared 28% YTD, gave 29% return in last 1-year, fell 12% in last 2-years, and gave 52% return in last 3-years.

Novartis India Financial Performance: The company for the quarter ended March 31, 2023 announced its standalone total income at Rs 92.50 crore, up 4.48% as against its last quarter total income of Rs 88.53 crore. It announced its recent quarter net profit after tax at Rs 25.02 crore.

Novartis India About: Headquartered in Basel, Switzerland, it is a leading global medicines company. It discovers and develops breakthrough treatments and find new ways to deliver them to as many people as possible. It uses innovative science and digital technologies to create transformative treatments in areas of great medical need, according to its official website.

Disclaimer: The stock just highlights the dividend and is not a recommendation to buy, sell or hold. We have not done fundamental or technical analysis and have no opinion on the stock mentioned. Neither, the author nor Greynium Information Technologies should be held liable for ay losses. Please consult a professional advisor.